Both histological biomarkers, such as tumor differentiation grade and lymph node invasion, and genetic biomarkers, including KRAS and BRAF mutations as well as microsatellite instability (MSI), are essential in colorectal cancer (CRC) for identifying patients at higher risk of recurrence or progression. This evidence concerns the gene KRAS and colorectal carcinoma.